Is glucose-6-phosphatase dehydrogenase deficiency associated with severe outcomes in hospitalized COVID-19 patients?
Abstract Glucose-6-phosphate dehydrogenase deficiency (G6PDd) is known to suppress the antioxidant system and is likely to aggravate severity of COVID-19, which results in a pro-oxidant response. This possible association has not been explored adequately in human studies. In this research, we report...
Guardado en:
Autores principales: | Nitya Kumar, AbdulKarim AbdulRahman, Abdulla Ismaeel AlAwadhi, Manaf AlQahtani |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6d06403b22444337b64d678cb4f75700 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The effect of ABO blood group and antibody class on the risk of COVID-19 infection and severity of clinical outcomes
por: Marwa Ali Almadhi, et al.
Publicado: (2021) -
Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency
por: Y ZahedPasha, et al.
Publicado: (2006) -
Correcting glucose-6-phosphate dehydrogenase deficiency with a small-molecule activator
por: Sunhee Hwang, et al.
Publicado: (2018) -
Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease
por: Manaf AlQahtani, et al.
Publicado: (2021) -
Evaluation of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency in Brazil.
por: Stephanie Zobrist, et al.
Publicado: (2021)